Purpose of ReviewTo highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity.Recent FindingsObesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established.SummaryThe evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.

Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications / Guglielmi, Valeria; Bettini, Silvia; Sbraccia, Paolo; Busetto, Luca; Pellegrini, Massimo; Yumuk, Volkan; Colao, Anna Maria; El Ghoch, Marwan; Muscogiuri, Giovanna. - In: CURRENT OBESITY REPORTS. - ISSN 2162-4968. - 12:2(2023), pp. 127-146. [10.1007/s13679-023-00502-7]

Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications

Pellegrini, Massimo;El Ghoch, Marwan;
2023

Abstract

Purpose of ReviewTo highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity.Recent FindingsObesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established.SummaryThe evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.
2023
12
2
127
146
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications / Guglielmi, Valeria; Bettini, Silvia; Sbraccia, Paolo; Busetto, Luca; Pellegrini, Massimo; Yumuk, Volkan; Colao, Anna Maria; El Ghoch, Marwan; Muscogiuri, Giovanna. - In: CURRENT OBESITY REPORTS. - ISSN 2162-4968. - 12:2(2023), pp. 127-146. [10.1007/s13679-023-00502-7]
Guglielmi, Valeria; Bettini, Silvia; Sbraccia, Paolo; Busetto, Luca; Pellegrini, Massimo; Yumuk, Volkan; Colao, Anna Maria; El Ghoch, Marwan; Muscogiuri, Giovanna
File in questo prodotto:
File Dimensione Formato  
13679_2023_Article_502.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.1 MB
Formato Adobe PDF
1.1 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1308627
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact